M&A in pharma
Explores the merits of mega-deal in contrast to a more measured portfolio growth strategy
Global Image Dermatology Drug Market, 2005-2012, The
High-Growth Opportunities in Aesthetic Medicine
| Publication Date | November 2005 |
| ISBN | n/a |
| Pages | 153 |
| Tables | 23 |
| Figures | 17 |
Print £825 $1295 |
Add to Basket |
PDF £795 $1250 Single user |
Add to Basket |
PDF £4600 $7215 Companywide user |
Add to Basket |
Examines the global market for aesthetic dermatologicals and specialty physician-dispensed drugs to treat conditions associated with deficits in physical image and form.
Examines the global market for aesthetic dermatologicals and specialty physician-dispensed drugs to treat conditions associated with deficits in physical image and form. Drugs such as botulinum toxins, retinoids, acid peels, 5-alpha reductase and lipase inhibitors associated with cutaneous ageing, photodamage, pigmentation defects, alopecia, and the lipodermal disorders of obesity and gynoid lipodystrophy are critically discussed to provide a detailed analysis of the high-growth market sector estimated at US$1.8 billion in 2005 and forecast to increase by 114% to US$3.9 billion by 2012. The report includes insights for product extension and optimization, sales forecasts to 2012, and impact of late-stage pipeline drugs on the market. Therapy area forecasting and illustrative market data and analysis is also presented to gain insight into top-performing products and therapy areas.
REPORT HIGHLIGHTS AND KEY FINDINGS
- Critical analysis of alopecia, cutaneous ageing, photodamage, pigmentation deficits, obesity, cellulite and other lipodermal conditions
- Comprehensive review of epidemiological, aetiological, and therapeutic data for 5 key therapy areas
- Analysis of over 20 marketed products and inclusion of 45 R&D candidates identified in preclinical to clinical stages of development
- Sales estimates (US$) to 2012 for critical therapy areas
- Strategic insights for life-cycle optimization and product development
- Evaluation of leading products and major competitors
- Emerging markets identified and sector analysis
- Trend analysis of industry events and activities over past 2 years
- Detailed R&D themes and clusters by therapy area
- Data generation on sector and market values between 2004 and 2012 and therapy forecasts by 2020 (US$)
- High revenue-yielding prospects identified with projected sales estimations
- R&D pipeline positioning for all therapy areas
- Market insights for product development and drug promotion
WHAT CAN I LEARN FROM THIS REPORT?
- What the main therapy areas are within the image dermatology field
- What the current treatment options are for alopecia, cutaneous ageing, photodamage, hyperand hypopigmentation disorders, and obesity
- Who the market leaders are in the image dermatology field
- Which premarket drugs are identified as potential blockbusters
- What factors are involved in driving the aesthetic dermatology market
- What the sales predictions are for botulinum toxins, retinoids, anorectics, lipase inhibitors, 5-alpha reductase inhibitors, antiandrogenics, hydroquinones, and tretinoin to 2012
- Which therapy areas are forecast for high-value growth over the next decade
- Which companies are developing novel drugs for aesthetic indications
- What are the unmet needs in the antiageing and image dermatology field
- Which therapy areas are niche market opportunities
- What the future outlook holds for marketed dermatologicals associated with ageing or lifestyle dissatisfaction
- What the research and development trends are in image dermatology
- Which molecules and compounds are being evaluated with potential indications for antiageing, aesthetics or lifestyle
- Which are the top prospects for image dermatology over the next decade and to 2020
COMPANIES MENTIONED IN REPORT
ABBOTT LABORATORIES SERONOALIZYME SHIONOGI
ALLERGAN SOLVAY PHARMACEUTICALS
AMGEN STIEFEL LABORATORIES
AMYLIN PHARMACEUTICALS TARGACEPT
ARENA PHARMACEUTICALS VALEANT PHARMACEUTICALS
ASTELLAS PHARMA VERNALIS
BARRIER THERAPEUTICS WYETH
BERTEK PHARMACEUTICALS
BIOACCELERATE
BIOTECON THERAPEUTICS
BIOVITRIUM
BRISTOL-MYERS SQUIBB
CHIRON
CURIS
DAINIPPON SUMITOMO PHARMACEUTICALS
EISAI
ELAN
ENHANCE BIOTECH
EPITAN
FASGEN
GALDERMA
GENAERA
GLADES PHARMACEUTICALS
GLAXOSMITHKLINE
GENADERM
INAMED
INTERCYTEX
IPSEN
ISOLAGEN
KARO BIO
LIGAND
MENTOR
MERCK
MERZ PHARMA
METABOLIC PHARMACEUTICALS
MILLENNIUM
NASTECH
NEUROGEN
OBAGI MEDICAL PRODUCTS
ORTHO-MCNEIL PHARMACEUTICALS
PFIZER
PHERIN PHARMACEUTICALS
PREDIX PHARMA
PHYTOPHARM
ROCHE
SANOFI-AVENTIS
SAPPHIRETHERAPEUTICS
Executive Summary
Objectives of the Report Briefing
Research Methodology
Chapter 1 Introduction to Antiageing and Image Dermatology Ageing and life Enhancement
What are Antiageing and Life Enhancement Pharmacotherapies?
Ageing, Lifestyle Conditions, and Dermatology
Alopecia
Dermal Ageing
Photodamage and Solar Radiation
Pollution and Dermal Damage
Dermal Pigmentation
Hyerpigmentation and Hypopigmentation Disorders
Biological Basis to Pigmentation: Melanogenesis and Photoprotection
Cellular Mechanisms of Melanogenesis and Photoprotection
Hyperpigmentation Disorders
Hypopigmentation Disorders
Vitiligo
Albinism
Postinflammatory Hypopigmentation
Lipodermal Disorders
Gynoid Lipodystrophy
The Development of Cellulite
Treatments Options for Cellulite
Obesity
Obesity Prevalence
Types of Obesity
Measuring and Diagnosing Obesity
Aetiological Aspects of Obesity
Physiological Aspects of Hunger and Satiety
Health Risks of Obesity
Psychosocial Aspects of Obesity
Alopecia Drug Market Overview
Market Forecasts for Alopecia Products
Market Analysis for the Alopecia Drug Market
Propecia (Finasteride) - Merck
Rogaine/Regaine (Minoxidil) - Pfizer
Product Extension Strategy Insights for Alopecia Products
Product Extension Strategy Insights for Finasteride
Product Extension Strategy Insights for Minoxidil
Future Considerations for Drugs to Treat Alopecia
Drug Development Prospects
BIO024 - Genaderm
Other Clinical Candidates
Cutaneous Ageing
Dermal Ageing Product Market Overview
Market Forecasts for Dermal Ageing Products
Market Analysis for Cutaneous Ageing/Photodamage Products
Market Insights and Strategies for the Botulinum Toxin Sector
Direct Competition to Botox
Botulinum Toxin Products in Asia and South America
Product Extension Strategy Insights for Botulinum Toxin Products
Market Insights and Strategies for the Topical Antiageing Product Sector
Product Extension Strategy Insights for Topical Antiageing Products
Tretinoin
Isotretinoin
Tazarotene
Idebenone
Acid Peel Products
Future Considerations and Market Insights for the Cutaneous Antiageing
Product Sector
Dermal Pigmentation Conditions
Market Forecasts for Dermal Pigmentation Products
Market Analysis of the Dermal Pigmentation Product Sector
Market Insights and Potential Product Development Strategies for Hyperpigmentation
Conditions
Hydroquinone
Tretinoin
Azelaic Acid
Market Insights and Potential Product Development Strategies for Hypopigmentation
Conditions
Induced Photoprotective Melanogenesis
Therapeutic, Prophylactic, and Cosmetic Markets for Photoprotective Melanogenesis
Solar Allergies/Polymorphous Light Eruption
Other Hypopigmentation Conditions
Skin Cancer Prophylaxis
Cosmetic-Medical Indications
Future Considerations and Market Outlook for the Dermal Pigmentation Therapy Area
Lipodermal Conditions
Gynoid Lipodystrophy (Cellulite)
Novel Pharmacotherapeutics for Cellulite
BIO303 - Enhance Biotech/Bioaccelerate
Phosphatidylcholine (Lecithin)
Redeveloping Old Molecules for New Cosmetic Indications
Obesity
Market Analysis for Antiobesity Drugs
Market Forecasts for Antiobesity Drugs
Antiobesity Product Extension Strategies and Insights
Sibutramine - (Meridia/Reductil) Abbott Laboratories
Market Outlook for Sibutramine
Orlistat
Class Competition - ATL-962 (Cetilistat) Alizyme
Product Extension Strategy Insights for Orlistat
Antiobesity Drugs at the Premarket Authorization Stage
Rimonabant
Safety and Efficacy Data
Lipodermal Disorders - Future Considerations and Market Insights
Gynoid Lipodystrophy
Obesity
Emerging Weight Regulation and Lipid Metabolism Market Opportunities
Appetite Stimulation
Lipodystrophies
Alopecia
Research and Development Overview
Hedgehog Agonists - Curis
ICX-TRC - Intercytex
BIO024 - Genaderm/Bioaccelerate
Dermal Ageing
Research and Development Overview
Dysport/Reloxin - Ipsen/Inamed
Autologous Cell Therapy - Isolagen
17-Beta Oestradiol (E2) - University of Michigan/Pfizer
Pigmentation Conditions
Research and Development Overview
EPT1647 - Epitan
Lipodermal Conditions
Gynoid Lipodystrophy
Research and Development Overview
BIO303 - Enhance Biotech/Bioaccelerate
Obesity
Research and Development Overview
Market Analysis and Therapy Forecasting
Dermatology: Alopecia, Dermal Ageing, Pigmentation Disorders and
Lipodermal Conditions
Therapy Area Forecasts
Market Share of Dermatological Therapy Areas
Comparative Analysis: Product Sales
Dermatology Therapy Areas
Prospect Mining
Dermatological Drug Prospects in the Antiageing and Life Enhancement
Therapy Market
Alopecia
Dermal Ageing
Dermal Pigmentation
Lipodermal Conditions
Alopecia - Key Data Points
Dermal Ageing and Pigmentation Disorders - Key Data Points
Lipodermal Conditions - Key Data Points
Bibliography and Reference Sources
Table 1.2 Features of Intrinsic Chronological Cutaneous Ageing and Photoageing
Table 1.3 Factors Associated with Dermal Ageing
Table 1.4 Types of Solar Radiation
Table 1.5 Common Hyperpigmentation Disorders
Table 1.6 Types of Hypopigmentation Disorders
Table 1.7 Calculating Body Mass Index
Table 1.8 Aetiological Factors Associated with Obesity
Table 1.9 Health Risks and Comorbidities Associated with Obesity
Table 1.10 Psychological, Behavioural, and Socioenvironmental Factors Associated with Obesity
Table 2.1 Estimated Global Sales & Forecasts of Drugs for Alopecia (US$m), 2004-2012
Table 2.2 Estimated Global Sales & Forecasts of Dermal Antiageing Products, 2004-2012
Table 2.3 Topical Antiageing/Photodamage Products, 2005
Table 2.4 Estimated Global Sales & Forecasts of Products for Pigmentation Conditions, 2004-2012
Table 2.5 Pharmaceutical Products to Treat Common Dermal Pigmentation, 2005
Table 2.6 Estimated Global Sales & Forecasts of Antiobesity Drugs, 2004-2012
Table 3.1 Drugs in Development for Alopecia, 2005
Table 3.2 Drugs in Development for Dermal Ageing, 2005
Table 3.3 Drugs in Development for Pigmentation Disorders, 2005
Table 3.4 Drugs in Development for Gynoid Lipodystrophy (Cellulite), 2005
Table 3.5 Drugs in Development for Obesity, 2005
Table 3.6 Drugs in Development for Appetite Stimulation and Lipodystrophy, 2005
Table 4.1 Global Drug Market for Dermatological Conditions Associated with Ageing and Lifestyle Dysfunction (US$m), 2004-2012
Figure 2.1 Projected Growth Rates for Alopecia Drugs, 2005-2012
Figure 2.2 Estimated Global Sales of Alopecia Drugs, 2004-2012
Figure 2.3 Projected Growth Rates for Cutaneous Antiageing Products, 2005 & 2012
Figure 2.4 Estimated Global Sales of Dermal Antiageing Products, 2004-2012
Figure 2.5 Projected Growth Rates of Products for Pigmentation Conditions, 2005 & 2012
Figure 2.6 Estimated Global Sales of Products for Pigmentation Conditions, 2004-2012
Figure 2.7 Projected Growth Rates of Current Antiobesity Drugs, 2005-2012
Figure 2.8 Estimated Global Sales of Antiobesity Drugs, 2004-2012
Figure 2.9 Main Drivers of Growth in the Antiobesity Pharmacotherapeutic Market
Figure 4.1 Dermatological Therapy Area Forecasts, 2005 & 2012 (US$m)
Figure 4.2 Market Share of Dermatological Therapy Areas, 2005 & 2012
Figure 4.3 Comparative Analysis of Leading Dermatology Products, 2004-2012 (US$m)
Figure 4.4 Key Alopecia Drug Prospects in the Antiageing and Life Enhancement Development Pipeline, 2005
Figure 4.5 Key Dermal Ageing Prospects in the Antiageing and Life Enhancement Development Pipeline, 2005
Figure 4.6 Key Dermal Pigmentation Drug Prospects in the Antiageing and Life Enhancement Development Pipeline, 2005
Figure 4.7 Key Lipodermal Drug Prospects in the Antiageing and Life Enhancement Development Pipeline, 2005
Objectives of the Report Briefing
Research Methodology
Chapter 1 Introduction to Antiageing and Image Dermatology Ageing and life Enhancement
What are Antiageing and Life Enhancement Pharmacotherapies?
Ageing, Lifestyle Conditions, and Dermatology
Alopecia
Prevalence of Alopecia
Alopecia as a Lifestyle Problem
The Normal Hair Growth Cycle
Types of Alopecia
Dermal Ageing
Photodamage and Solar Radiation
Pollution and Dermal Damage
Dermal Pigmentation
Hyerpigmentation and Hypopigmentation Disorders
Biological Basis to Pigmentation: Melanogenesis and Photoprotection
Cellular Mechanisms of Melanogenesis and Photoprotection
Hyperpigmentation Disorders
Hypopigmentation Disorders
Vitiligo
Albinism
Postinflammatory Hypopigmentation
Lipodermal Disorders
Gynoid Lipodystrophy
The Development of Cellulite
Treatments Options for Cellulite
Obesity
Obesity Prevalence
Types of Obesity
Measuring and Diagnosing Obesity
Aetiological Aspects of Obesity
Physiological Aspects of Hunger and Satiety
Health Risks of Obesity
Psychosocial Aspects of Obesity
Chapter 2 Image Dermatology Drug Markets
AlopeciaAlopecia Drug Market Overview
Market Forecasts for Alopecia Products
Market Analysis for the Alopecia Drug Market
Propecia (Finasteride) - Merck
Rogaine/Regaine (Minoxidil) - Pfizer
Product Extension Strategy Insights for Alopecia Products
Product Extension Strategy Insights for Finasteride
Product Extension Strategy Insights for Minoxidil
Future Considerations for Drugs to Treat Alopecia
Drug Development Prospects
BIO024 - Genaderm
Other Clinical Candidates
Cutaneous Ageing
Dermal Ageing Product Market Overview
Market Forecasts for Dermal Ageing Products
Market Analysis for Cutaneous Ageing/Photodamage Products
Market Insights and Strategies for the Botulinum Toxin Sector
Direct Competition to Botox
Botulinum Toxin Products in Asia and South America
Product Extension Strategy Insights for Botulinum Toxin Products
Market Insights and Strategies for the Topical Antiageing Product Sector
Product Extension Strategy Insights for Topical Antiageing Products
Tretinoin
Isotretinoin
Tazarotene
Idebenone
Acid Peel Products
Future Considerations and Market Insights for the Cutaneous Antiageing
Product Sector
Dermal Pigmentation Conditions
Market Forecasts for Dermal Pigmentation Products
Market Analysis of the Dermal Pigmentation Product Sector
Market Insights and Potential Product Development Strategies for Hyperpigmentation
Conditions
Hydroquinone
Tretinoin
Azelaic Acid
Market Insights and Potential Product Development Strategies for Hypopigmentation
Conditions
Induced Photoprotective Melanogenesis
Therapeutic, Prophylactic, and Cosmetic Markets for Photoprotective Melanogenesis
Solar Allergies/Polymorphous Light Eruption
Other Hypopigmentation Conditions
Skin Cancer Prophylaxis
Cosmetic-Medical Indications
Future Considerations and Market Outlook for the Dermal Pigmentation Therapy Area
Lipodermal Conditions
Gynoid Lipodystrophy (Cellulite)
Novel Pharmacotherapeutics for Cellulite
BIO303 - Enhance Biotech/Bioaccelerate
Phosphatidylcholine (Lecithin)
Redeveloping Old Molecules for New Cosmetic Indications
Obesity
Market Analysis for Antiobesity Drugs
Market Forecasts for Antiobesity Drugs
Antiobesity Product Extension Strategies and Insights
Sibutramine - (Meridia/Reductil) Abbott Laboratories
Market Outlook for Sibutramine
Orlistat
Class Competition - ATL-962 (Cetilistat) Alizyme
Product Extension Strategy Insights for Orlistat
Antiobesity Drugs at the Premarket Authorization Stage
Rimonabant
Safety and Efficacy Data
Lipodermal Disorders - Future Considerations and Market Insights
Gynoid Lipodystrophy
Obesity
Emerging Weight Regulation and Lipid Metabolism Market Opportunities
Appetite Stimulation
Lipodystrophies
Chapter 3 Drugs in Research and Development
IntroductionAlopecia
Research and Development Overview
Hedgehog Agonists - Curis
ICX-TRC - Intercytex
BIO024 - Genaderm/Bioaccelerate
Dermal Ageing
Research and Development Overview
Dysport/Reloxin - Ipsen/Inamed
Autologous Cell Therapy - Isolagen
17-Beta Oestradiol (E2) - University of Michigan/Pfizer
Pigmentation Conditions
Research and Development Overview
EPT1647 - Epitan
Lipodermal Conditions
Gynoid Lipodystrophy
Research and Development Overview
BIO303 - Enhance Biotech/Bioaccelerate
Obesity
Research and Development Overview
Chapter 4 Market Analysis, Therapy Forecasting, and Prospect Mining
Introduction: Data Analysis, Therapy Forecasting, and Prospect MiningMarket Analysis and Therapy Forecasting
Dermatology: Alopecia, Dermal Ageing, Pigmentation Disorders and
Lipodermal Conditions
Therapy Area Forecasts
Market Share of Dermatological Therapy Areas
Comparative Analysis: Product Sales
Dermatology Therapy Areas
Prospect Mining
Dermatological Drug Prospects in the Antiageing and Life Enhancement
Therapy Market
Alopecia
Dermal Ageing
Dermal Pigmentation
Lipodermal Conditions
Chapter 5 Report Synopsis
DermatologyAlopecia - Key Data Points
Dermal Ageing and Pigmentation Disorders - Key Data Points
Lipodermal Conditions - Key Data Points
Bibliography and Reference Sources
List of Tables
Table 1.1 Types of AlopeciaTable 1.2 Features of Intrinsic Chronological Cutaneous Ageing and Photoageing
Table 1.3 Factors Associated with Dermal Ageing
Table 1.4 Types of Solar Radiation
Table 1.5 Common Hyperpigmentation Disorders
Table 1.6 Types of Hypopigmentation Disorders
Table 1.7 Calculating Body Mass Index
Table 1.8 Aetiological Factors Associated with Obesity
Table 1.9 Health Risks and Comorbidities Associated with Obesity
Table 1.10 Psychological, Behavioural, and Socioenvironmental Factors Associated with Obesity
Table 2.1 Estimated Global Sales & Forecasts of Drugs for Alopecia (US$m), 2004-2012
Table 2.2 Estimated Global Sales & Forecasts of Dermal Antiageing Products, 2004-2012
Table 2.3 Topical Antiageing/Photodamage Products, 2005
Table 2.4 Estimated Global Sales & Forecasts of Products for Pigmentation Conditions, 2004-2012
Table 2.5 Pharmaceutical Products to Treat Common Dermal Pigmentation, 2005
Table 2.6 Estimated Global Sales & Forecasts of Antiobesity Drugs, 2004-2012
Table 3.1 Drugs in Development for Alopecia, 2005
Table 3.2 Drugs in Development for Dermal Ageing, 2005
Table 3.3 Drugs in Development for Pigmentation Disorders, 2005
Table 3.4 Drugs in Development for Gynoid Lipodystrophy (Cellulite), 2005
Table 3.5 Drugs in Development for Obesity, 2005
Table 3.6 Drugs in Development for Appetite Stimulation and Lipodystrophy, 2005
Table 4.1 Global Drug Market for Dermatological Conditions Associated with Ageing and Lifestyle Dysfunction (US$m), 2004-2012
List of Figures
Figure 1.1 Factors Involved in Normal Body Weight RegulationFigure 2.1 Projected Growth Rates for Alopecia Drugs, 2005-2012
Figure 2.2 Estimated Global Sales of Alopecia Drugs, 2004-2012
Figure 2.3 Projected Growth Rates for Cutaneous Antiageing Products, 2005 & 2012
Figure 2.4 Estimated Global Sales of Dermal Antiageing Products, 2004-2012
Figure 2.5 Projected Growth Rates of Products for Pigmentation Conditions, 2005 & 2012
Figure 2.6 Estimated Global Sales of Products for Pigmentation Conditions, 2004-2012
Figure 2.7 Projected Growth Rates of Current Antiobesity Drugs, 2005-2012
Figure 2.8 Estimated Global Sales of Antiobesity Drugs, 2004-2012
Figure 2.9 Main Drivers of Growth in the Antiobesity Pharmacotherapeutic Market
Figure 4.1 Dermatological Therapy Area Forecasts, 2005 & 2012 (US$m)
Figure 4.2 Market Share of Dermatological Therapy Areas, 2005 & 2012
Figure 4.3 Comparative Analysis of Leading Dermatology Products, 2004-2012 (US$m)
Figure 4.4 Key Alopecia Drug Prospects in the Antiageing and Life Enhancement Development Pipeline, 2005
Figure 4.5 Key Dermal Ageing Prospects in the Antiageing and Life Enhancement Development Pipeline, 2005
Figure 4.6 Key Dermal Pigmentation Drug Prospects in the Antiageing and Life Enhancement Development Pipeline, 2005
Figure 4.7 Key Lipodermal Drug Prospects in the Antiageing and Life Enhancement Development Pipeline, 2005